Bioretec Oy Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Alan Donze

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenure1.3yrs
Board average tenure1.8yrs

Recent management updates

Recent updates


CEO

Alan Donze (59 yo)

less than a year

Tenure

Mr. Alan Donze is Chief Executive Officer of Bioretec Oy from May 20, 2024. Mr. Donze has held senior leadership positions for a number of other medical device and technology companies including Smith Neph...


Leadership Team

NamePositionTenureCompensationOwnership
Alan Donze
Chief Executive Officerless than a yearno datano data
Johanna Salko
Chief Financial Officer3.8yrsno datano data
Esa Hallinen
Director of Operations1.3yrsno datano data
Timo Lehtonen
Chief Technology Officerless than a yearno datano data
Rami Ojala
Sales & Marketing Director2.9yrsno datano data

1.3yrs

Average Tenure

57yo

Average Age

Experienced Management: BRETEC's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Tomi Numminen
Chairman of the Board8.6yrsno datano data
Kustaa Poutiainen
Director1.6yrsno datano data
Sarah Van Hellenberg Hubar-Fisher
Director3.7yrsno datano data
Michael Piccirillo
Director6.9yrsno datano data
Paivi Malinen
Director2.7yrsno datano data
Klaus Dresing
Member of Scientific Advisory Boardno datano datano data
Fan Liu
Member of Scientific Advisory Board1.8yrsno datano data
Theddy Slongo
Member of Scientific Advisory Boardno datano datano data
Jeffrey Wang
Member of Scientific Advisory Board1.8yrsno datano data
Richard Assaker
Member of Scientific Advisory Board1.8yrsno datano data
Stefan Rammelt
Member of Scientific Advisory Board1.3yrsno datano data
Verena Schreiber
Member of Scientific Advisory Board1.3yrsno datano data

1.8yrs

Average Tenure

53yo

Average Age

Experienced Board: BRETEC's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 07:47
End of Day Share Price 2024/12/23 00:00
EarningsN/A
Annual EarningsN/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bioretec Oy is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Daniel LepistöDanske Bank
Marianne PalmuInderes Oy
Frans-Mikael RostedtInderes Oy